Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW A ENGELBRECHT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1861406134
CMS profile
129972
Location
ASHEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,316.99

123 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,316.99 123

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $201.38 13
Biogen, Inc. $198.09 8
Novartis Pharmaceuticals Corporation $130.43 12
Neurocrine Biosciences, Inc. $92.66 4
Avanir Pharmaceuticals, Inc. $80.20 4
Amgen Inc. $76.03 4
Biohaven Pharmaceutical Holding Company Ltd. $74.04 4
UCB, Inc. $68.87 3
Teva Pharmaceuticals USA, Inc. $67.18 3
JAZZ PHARMACEUTICALS INC. $66.54 3
Celgene Corporation $66.15 4
GENZYME CORPORATION $63.04 3
Lilly USA, LLC $57.80 3
Horizon Therapeutics plc $57.14 3
SK Life Science, Inc. $55.75 3
Alexion Pharmaceuticals, Inc. $52.58 3
Merz Pharmaceuticals, LLC $51.79 2
MDD US Operations, LLC $49.63 3
CATALYST PHARMACEUTICALS, INC. $49.37 2
Banner Life Sciences, LLC $46.99 2
UPSHER-SMITH LABORATORIES LLC $44.45 2
EMD Serono, Inc. $42.06 2
Cala Health, Inc. $41.98 2
Amneal Pharmaceuticals LLC $41.24 2
Janssen Pharmaceuticals, Inc $38.82 2
Lundbeck LLC $38.04 2
Abbott Laboratories $31.99 2
Allergan, Inc. $31.34 2
EISAI INC. $30.68 2
Sunovion Pharmaceuticals Inc. $29.63 2
Alnylam Pharmaceuticals Inc. $26.88 1
CSL Behring $26.08 1
Grifols USA, LLC $24.91 1
ACADIA Pharmaceuticals Inc $24.05 1
Mallinckrodt Hospital Products Inc. $23.45 1
ARGENX US, INC. $23.10 1
Aprecia Pharmaceuticals, LLC $22.13 1
Exeltis, USA Inc. $20.90 1
LivaNova USA, Inc. $19.20 1
GRT US Holding, Inc. $18.24 1
HOSPIRA, INC. $18.15 1
Acorda Therapeutics, Inc $17.83 1
Scilex Pharmaceuticals Inc. $17.81 1
AstraZeneca Pharmaceuticals LP $16.94 1
Supernus Pharmaceuticals, Inc. $14.44 1
PFIZER INC. $13.67 1
MITSUBISHI TANABE PHARMA AMERICA, INC. $13.32 1

Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW A ENGELBRECHT

NPI 1861406134 · CMS profile ID 129972

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ASHEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861406134?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW A ENGELBRECHT, NPI 1861406134, CMS profile ID 129972. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861406134?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MATTHEW A ENGELBRECHT, NPI 1861406134, CMS profile ID 129972. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861406134?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MATTHEW A ENGELBRECHT, NPI 1861406134, CMS profile ID 129972, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 123 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1861406134?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

123 matching records · $2,316.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 123 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 123.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Cala Health, Inc. $15.9908/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 901463333 CMS
EISAI INC. $15.9608/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908063047 CMS
MDD US Operations, LLC $12.9307/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951616825 CMS
ARGENX US, INC. $23.1007/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951625899 CMS
Merz Pharmaceuticals, LLC $24.2107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943792409 CMS
SK Life Science, Inc. $19.9807/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940690189 CMS
Biohaven Pharmaceutical Holding Company Ltd. $17.7006/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923583447 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $13.3206/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940569947 CMS
ABBVIE INC. $22.0106/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890922893 CMS
Avanir Pharmaceuticals, Inc. $17.4806/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935962415 CMS
Grifols USA, LLC $24.9106/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918677925 CMS
Lilly USA, LLC $18.2606/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918228369 CMS
Novartis Pharmaceuticals Corporation $21.7206/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893619901 CMS
Novartis Pharmaceuticals Corporation $4.2206/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893619899 CMS
Biogen, Inc. $12.7206/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923439907 CMS
Biogen, Inc. $19.9906/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923413109 CMS
CATALYST PHARMACEUTICALS, INC. $25.3906/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950295657 CMS
ABBVIE INC. $3.9806/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890922891 CMS
Amgen Inc. $24.5406/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939245177 CMS
Teva Pharmaceuticals USA, Inc. $22.8105/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954654192 CMS
Novartis Pharmaceuticals Corporation $3.7605/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893619897 CMS
Acorda Therapeutics, Inc $17.8305/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920336139 CMS
Janssen Pharmaceuticals, Inc $19.6305/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886533165 CMS
Alexion Pharmaceuticals, Inc. $15.6505/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915642555 CMS
Biogen, Inc. $98.7105/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923456027 CMS
Abbott Laboratories $15.5305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914280557 CMS
Avanir Pharmaceuticals, Inc. $21.5305/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935949199 CMS
Biogen, Inc. $10.6205/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923438025 CMS
Banner Life Sciences, LLC $22.7705/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957719221 CMS
SK Life Science, Inc. $15.4905/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940690145 CMS
Sunovion Pharmaceuticals Inc. $9.6605/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921115977 CMS
Novartis Pharmaceuticals Corporation $4.7004/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893619895 CMS
ABBVIE INC. $4.3404/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890922889 CMS
Supernus Pharmaceuticals, Inc. $14.4404/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952948993 CMS
Teva Pharmaceuticals USA, Inc. $23.7804/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954654299 CMS
ABBVIE INC. $16.8204/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890922887 CMS
ABBVIE INC. $20.8604/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890922885 CMS
EMD Serono, Inc. $15.7904/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941506125 CMS
MDD US Operations, LLC $19.7104/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951616823 CMS
Lundbeck LLC $16.8904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945745547 CMS
Alexion Pharmaceuticals, Inc. $12.7304/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915355639 CMS
Novartis Pharmaceuticals Corporation $15.7603/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893619893 CMS
Neurocrine Biosciences, Inc. $21.4003/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963282799 CMS
ABBVIE INC. $26.4603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890922883 CMS
Allergan, Inc. $16.8003/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889878463 CMS
Janssen Pharmaceuticals, Inc $19.1903/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886533161 CMS
Biohaven Pharmaceutical Holding Company Ltd. $18.8503/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923583445 CMS
Amneal Pharmaceuticals LLC $20.0903/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956578355 CMS
Abbott Laboratories $16.4603/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920561933 CMS
Horizon Therapeutics plc $17.5503/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937617753 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,734.60 159
PY2020 $877.94 51
PY2021 $2,048.48 124
PY2022 $2,316.99 123
PY2023 $2,446.57 120
PY2024 $2,987.57 117
PY2025 $2,927.92 166

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $90,123.43 88
PY2024 Principal investigator $274,429.62 94
PY2023 Recipient $2,043.08 1
PY2023 Principal investigator $473,903.36 51
PY2022 Recipient $30,901.00 2
PY2022 Principal investigator $30,194.94 80
PY2021 Principal investigator $63,248.75 78
PY2020 Principal investigator $16,057.00 4
PY2019 Principal investigator $10,098.13 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $400.00 12/04/2025 Non-covered Recipient Entity
Elevate Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184302803
Principal investigator 1 Ipsen Innovation $141.75 11/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295795
Principal investigator 1 Ipsen Innovation $44.55 10/10/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295791
Principal investigator 1 Ipsen Innovation $100.00 10/10/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295793
Principal investigator 1 Ipsen Innovation $44.55 09/15/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295773
Principal investigator 1 Ipsen Innovation $44.55 09/15/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295775
Principal investigator 1 Ipsen Innovation $200.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295771
Principal investigator 1 Ipsen Innovation $60.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295777
Principal investigator 1 Ipsen Innovation $141.75 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295779
Principal investigator 1 Ipsen Innovation $44.55 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295781
Principal investigator 1 Ipsen Innovation $250.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295783
Principal investigator 1 Ipsen Innovation $180.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295785
Principal investigator 1 Ipsen Innovation $100.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295787
Principal investigator 1 Ipsen Innovation $150.00 09/05/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295789
Principal investigator 1 Ipsen Innovation $500.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295761
Principal investigator 1 Ipsen Innovation $1,000.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295763
Principal investigator 1 Ipsen Innovation $1,000.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295765
Principal investigator 1 Ipsen Innovation $1,600.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295767
Principal investigator 1 Ipsen Innovation $2,000.00 08/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295769
Principal investigator 1 Ipsen Innovation $44.55 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295749
Principal investigator 1 Ipsen Innovation $44.55 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295751
Principal investigator 1 Ipsen Innovation $44.55 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295753
Principal investigator 1 Ipsen Innovation $1,879.20 07/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295755
Principal investigator 1 Ipsen Innovation $450.00 07/14/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295759
Principal investigator 1 Eli Lilly and Company $685.00 07/09/2025 Non-covered Recipient Entity
ASHEVILLE ARTHRITIS AND OSTEOPOROSIS CENTER
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187876377
Principal investigator 1 Ipsen Innovation $350.00 07/07/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295757
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295707
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295709
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295717
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295719
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295721
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295731
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295733
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295735
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295739
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295741
Principal investigator 1 Ipsen Innovation $1,107.00 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295743
Principal investigator 1 Ipsen Innovation $1,858.95 06/30/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295745
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295705
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295711
Principal investigator 1 Ipsen Innovation $100.24 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295713
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295723
Principal investigator 1 Ipsen Innovation $100.24 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295725
Principal investigator 1 Ipsen Innovation $44.55 06/25/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295737
Principal investigator 1 Ipsen Innovation $2,149.20 06/20/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295729
Principal investigator 1 Ipsen Innovation $44.55 06/06/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295715
Principal investigator 1 Ipsen Innovation $44.55 06/06/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295727
Principal investigator 1 Ipsen Innovation $44.55 06/06/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295747
Principal investigator 1 Ipsen Innovation $44.55 05/21/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295703
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295663
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295665
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295667
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295669
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295671
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295673
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295677
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295679
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295681
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295683
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295685
Principal investigator 1 Ipsen Innovation $1,784.70 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295687
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295691
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295693
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295695
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295699
Principal investigator 1 Ipsen Innovation $1,107.00 04/28/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295701
Principal investigator 1 Ipsen Innovation $90.00 04/22/2025 Non-covered Recipient Entity
Asheville Neurology Specialists, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287874
Principal investigator 1 Ipsen Innovation $150.00 04/22/2025 Non-covered Recipient Entity
Asheville Neurology Specialists, Pa
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287876
Principal investigator 1 Ipsen Innovation $360.00 04/14/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295675
Principal investigator 1 Ipsen Innovation $44.55 04/04/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295689
Principal investigator 1 Ipsen Innovation $390.25 04/04/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295697
Principal investigator 1 Ipsen Innovation $720.00 03/10/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295661
Principal investigator 1 Eli Lilly and Company $25,952.00 02/10/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187879225
Principal investigator 1 Ipsen Innovation $1,784.70 01/31/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295643
Principal investigator 1 Ipsen Innovation $500.00 01/29/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295631
Principal investigator 1 Ipsen Innovation $1,107.00 01/27/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295637
Principal investigator 1 Ipsen Innovation $1,107.00 01/27/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295641
Principal investigator 1 Ipsen Innovation $2,149.20 01/27/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295659
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295633
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295635
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295639
Principal investigator 1 Ipsen Innovation $500.00 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295645
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295647
Principal investigator 1 Ipsen Innovation $500.00 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295649
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295651
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295653
Principal investigator 1 Ipsen Innovation $1,000.00 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295655
Principal investigator 1 Ipsen Innovation $44.55 01/03/2025 Non-covered Recipient Entity
Elligo Health Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184295657